THC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Tenet Healthcare Corp (THC) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock benefits from strong financial performance, positive analyst sentiment, and hedge fund buying activity, making it a compelling opportunity despite the lack of immediate trading signals.
The stock's technical indicators show mixed signals. The MACD is positive and contracting, suggesting potential bullish momentum. However, the RSI is neutral at 39.968, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below the pivot level of 194.695, with key support at 185.783 and resistance at 203.607. This indicates the stock is near support levels, which could present a buying opportunity.
Hedge funds are significantly increasing their positions in THC, with a 337.36% increase in buying over the last quarter.
Analysts have consistently raised price targets, with the most recent targets ranging from $242 to $283, reflecting strong confidence in the company's growth potential.
The company's financials for Q4 2025 showed robust growth, with revenue up 8.95% YoY, net income up 16.67% YoY, and EPS up 27.88% YoY.
No recent news or event-driven catalysts to drive immediate price action.
The stock's gross margin dropped slightly to 77.55%, down -0.40% YoY.
Technical indicators show bearish moving averages, which could indicate short-term downward pressure.
In Q4 2025, Tenet Healthcare reported strong financial performance with an 8.95% YoY increase in revenue to $5.53 billion, a 16.67% YoY increase in net income to $371 million, and a 27.88% YoY increase in EPS to $4.22. However, the gross margin slightly declined to 77.55%, down -0.40% YoY.
Analysts are overwhelmingly positive on THC, with multiple firms raising price targets recently. The highest target is $283 (Guggenheim), and the lowest is $242 (TD Cowen). Analysts highlight the company's strong fundamentals, demographic tailwinds, and growth in higher acuity surgeries as key drivers for future performance.
